Articles tagged with Pancreatic Cancer
Researchers at The Ohio State University Wexner Medical Center have developed a new 'virtual biopsy' method that accurately diagnoses precancerous pancreatic cysts with unprecedented accuracy. This diagnostic tool allows doctors to eliminate precancerous cysts and potentially save lives by identifying them early.
Researchers at American Friends of Tel Aviv University have developed a new treatment that triggers the self-destruction of pancreatic cancer cells. The innovative therapy has shown promising results in its early stages, providing hope for patients with pancreatic cancer.
Researchers from Queen Mary University of London and Zhengzhou University have developed a personalised vaccine system that can delay the onset of pancreatic cancer. The system was tested in mice, where it doubled their survival time compared to those without the vaccine.
Researchers at the University of South Australia are developing a new radioimmunotherapy agent to target and kill pancreatic cancer cells, potentially minimizing side effects. The treatment uses alpha particles to deposit energy inside cancer cells while leaving healthy tissue intact.
Researchers developed a new two-subtype system to classify pancreatic cancer tumors based on treatment response data from clinical trials. The study found that patients with basal-like tumors showed poor responses to common therapies and worse survival outcomes.
Scientists at Sanford Burnham Prebys Medical Discovery Institute identified a combination of two anti-cancer compounds that shrank pancreatic tumors in mice, supporting the immediate evaluation of the drugs in a clinical trial. The study provides rationale for an immediate clinical trial evaluating the 2 therapies
A study published in Nature Cell Biology has identified a protein called CD9 that drives growth of pancreatic cancer and could be a target for new treatments. The researchers found that CD9 is present on the surface of cancer stem cells, which are a driving force behind cancer growth.
A major study across 195 countries found that global death rates for pancreatic cancer and incidence rates for colorectal cancer increased by 10% between 1990 and 2017. The study also reported significant increases in cases of inflammatory bowel disease (IBD) and a rise in obesity-related risk factors for pancreatic cancer.
Researchers at Osaka University have developed a new radiation therapy method that targets pancreatic cancer cells directly, reducing side effects. The treatment uses a radioactive molecule that binds to specific proteins on stroma cells surrounding tumors, delivering high-energy doses of radiation to cancer tissue.
Researchers at Washington University and USF Health developed a peptide-based nanoparticle that delivers siRNA to suppress KRAS-driven cancer growth without adverse effects. The nanoparticles effectively target tumor cells, reducing tumor cell death and slowing cancer growth.
A new study published in Nature found that a single genetic mutation in the SF3B1 gene is associated with an increased risk of developing various types of cancer. The researchers discovered that this mutation leads to the production of abnormal RNA molecules, including noncoding DNA sequences that disrupt the genetic message.
Researchers at Georgetown University Medical Center developed a virtual review method that reduces the time needed to assess a cancer patient's tumor profile and suitability for clinical trials from 14 to 4 days. The method also increased the number of cases that could be assessed, with over 2,000 clinical trials evaluated.
A new treatment combination using stereotactic body radiotherapy and interleukin-12 has been shown to cure pancreatic cancer in mice by activating T-cells to attack cancer cells. The treatment also destroys pancreatic cells that have spread to the liver, a common site for metastatic disease.
A research team has identified a protein called Meflin in cancer-suppressing cells surrounding pancreatic cancer. Increasing Meflin levels can restrain cancer progression and may lead to new therapies against the disease.
A phase 1b/2 clinical trial found that adding cisplatin to a standard-of-care regimen resulted in 71% tumor shrinkage and increased survival beyond one year. The treatment showed encouraging results, with 64% of patients alive after one year and 40% alive after two years.
Certain fungi can expand their population over a thousand-fold, encouraging pancreatic cancer growth, according to a new study. The study found that treating mice with an antifungal drug reduced PDA tumor weight by 20-40 percent.
Researchers found PML dysfunction due to altered protein modification, specifically sumoylation, enables pancreatic tumor resistance to chemotherapeutic treatment. High PML expression and sumoylation are associated with better survival rates in patients.
Researchers have discovered a key mechanism behind pancreatic cancer's aggressive growth, which may help explain why promising drugs work and when they won't. The finding identifies a weakness in the cancer cells' metabolism that could be exploited to improve treatment outcomes.
A urine test that measures specific proteins found in urine can detect early-stage pancreatic cancer with nearly 95% accuracy. The UroPanc clinical study aims to validate this biomarker in a clinical setting, with the potential to develop a standardized urine test for clinicians to use as a diagnostic aid.
Researchers at Mayo Clinic discovered that inhibiting GSK-3 enzyme sensitizes pancreatic cancer cells to gemcitabine, a commonly used chemotherapy. This new approach may overcome resistance to chemotherapy and improve treatment outcomes for patients with pancreatic cancer.
Researchers at Johns Hopkins Medicine have discovered that the compound 4-HAP can reduce metastatic tumor formation in mouse models of human pancreatic cancer. By stiffening cells and overwhelming their ability to invade nearby tissue, 4-HAP may help halt the progression of disease-like behavior in pancreatic cancer cells.
Researchers at MD Anderson Cancer Center confirm ubiquitin specific protease 21 (UPS21) as a frequently amplified gene in pancreatic ductal adenocarcinoma (PDAC), a form of pancreatic cancer. Depletion of UPS21 impairs tumor growth, promoting malignant transformation and cancer cell stemness.
The American Society for Radiation Oncology (ASTRO) has released a new clinical guideline recommending the use of radiation therapy in pre-surgical, post-surgical, definitive and palliative settings. The guideline emphasizes a patient-centered approach integrating patients' values and preferences into treatment decisions.
A new study reveals pancreatic cancer cells invade and destroy nearby blood vessels, replacing them with tumor-lined structures. The process is driven by the interaction between the protein receptor ALK7 and the protein Activin, pointing to a possible target for future treatments.
A team of researchers at Georgetown University Medical Center has identified a chain of molecules critical for pancreatic ductal adenocarcinoma (PDAC) growth and survival. Inhibiting this 'Yap' biological network may effectively regress early-stage PDAC, and pairing it with other drugs could halt more advanced stage tumors.
Researchers found that abemaciclib, a chemotherapeutic agent effective in breast cancer, has synergy when combined with HuR and YAP1 inhibitors to inhibit cell growth. The study suggests new targets for improving the efficacy of this drug and overcoming drug resistance in pancreatic cancer.
Scientists at Huntsman Cancer Institute have discovered a way for cells to override genetic changes, potentially leading to more effective pancreatic cancer treatment. The study found that introducing PTF1A into normal cells prevented the formation of cancer cells and even reversed early-stage cancer cells back to healthy pancreas cells.
A study by Massachusetts General Hospital researchers has found a mutation in the RABL3 gene linked to hereditary forms of pancreatic cancer. The discovery may lead to earlier diagnoses and improved treatments for patients with strong family histories.
A phase 1 clinical trial found that combining AZD1775, a Wee1 inhibitor, with radiation and gemcitabine resulted in better-than-expected overall survival in patients with locally advanced pancreatic cancer. The median overall survival was 22 months, surpassing previous results for the same treatment combination.
Scientists have discovered a rare, inherited gene mutation that significantly increases the risk of pancreatic and other cancers. The RABL3 mutation was found in a family with multiple relatives diagnosed with pancreatic cancer, and zebrafish carrying the mutation also showed dramatically higher rates of cancer.
Researchers found that pancreatic tumours produce more perlecan to remodel the environment, helping cancer cells spread and resist chemotherapy. Lowering perlecan levels improved response to treatment in mouse models.
Researchers at Columbia University Irving Medical Center have identified a potential new therapy for pancreatic cancer. Their experimental compound, PTC596, has shown to be effective in combination with standard treatment, extending survival by three times in genetically engineered mice.
The USPSTF continues to recommend against routine screening for pancreatic cancer in asymptomatic adults due to its poor prognosis. This recommendation is based on the limited effectiveness and potential harms of screening in this population.
A new mouse model called KPP better mimics human cachexia symptoms, allowing researchers to control when cancer can be triggered. This advancement could lead to novel discoveries and identification of therapeutic targets for this devastating syndrome.
Two known gene mutations, KRAS and TP53, induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system. Mutations in these genes are closely linked to pancreatic ductal adenocarcinoma, a type of pancreatic cancer with a low five-year survival rate.
Researchers have identified a key protein involved in pancreatic cancer cell growth and found an antibody therapy that targets it, reducing tumour growth and increasing survival time in mice. The treatment combines the antibody with gemcitabine and achieves up to a sixfold increase in survival time compared to controls.
A nationwide study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that high blood sugar levels significantly increase the risk of pancreatic cancer. The study suggests that early detection of hyperglycemia and lifestyle modifications to improve glucose profiles may help lower this risk.
The Damon Runyon Cancer Research Foundation has awarded $3.5 million in fellowships to 15 early-career researchers, providing them with independence to pursue high-risk projects. The funding aims to support innovative cancer research and encourage promising young scientists to pursue careers in the field.
Researchers at Houston Methodist and MD Anderson Cancer Center have found a new immunotherapy to treat ovarian and pancreatic cancers by blocking the action of MFAP5 protein. This protein promotes tumor growth and reduces survival rates in patients with these cancers.
A new laboratory test using artificial intelligence tools has been shown to more accurately sort out which people with pancreatic cysts will go on to develop pancreatic cancers. The test, dubbed CompCyst, correctly identified patients who did not need surgery in over half of cases.
Researchers created a comprehensive test using machine learning algorithms to better guide patient management for pancreatic cysts, a precursor of pancreatic cancer. The test, called CompCyst, outperformed the current standard-of-care in an international study, avoiding surgery in 60% of patients who underwent unnecessary removal.
Researchers identified a compound that promotes a vigorous immune assault against pancreatic tumors, significantly shrinking them and improving survival. The compound, ADH-503, shifts the balance of myeloid cells toward those that activate T cells to attack cancer, making resistant cancers susceptible to immunotherapy.
Researchers discover a novel compound that activates CD11b receptors on white blood cells, promoting an anti-tumor immune response and overcoming resistance to immunotherapies. This breakthrough may lead to new treatments for the third deadliest cancer in the US.
Researchers at Cold Spring Harbor Laboratory discovered that pancreatic cancer cells destroy their own mitochondria to reduce reactive oxygen species and proliferate. Inhibiting the NIX pathway may prevent cancer cells from using energy to proliferate, offering a promising new target for therapies.
Researchers have identified a signaling pathway regulating macropinocytosis in pancreatic tumors, which could lead to personalized treatments. The study reveals that tumors can dynamically adjust their nutrient uptake, with some 'dialing up' or 'dialing down' macropinocytosis based on glutamine availability.
Researchers discovered that CA19-9, a complex sugar molecule, causes pancreatitis by recruiting the immune system and inducing deleterious biochemical reactions. Targeting CA19-9 with antibodies may prevent or treat pancreatitis and its progression to pancreatic cancer.
A widely recognized biomarker, CA19-9, is found to promote the development of pancreatic diseases and cancer in genetically engineered mice models. This discovery suggests new treatment strategies for pancreatic cancer and other cancer biomarkers.
Researchers found that FOLFIRINOX prolonged patients' lives by an average of 22.2 months, increasing the chances of complete tumor removal through surgery. More than two-thirds of cancers responded well to treatment, allowing for surgical removal.
Researchers have identified a new type of fibroblast in pancreatic cancer tumors that can evade immune detection. The discovery, published in Cancer Discovery, highlights the complex role of these cells in protecting cancer cells and could lead to new therapeutic strategies.
Researchers from the University of Oklahoma College of Medicine have identified ZIP4 as the trigger for muscle-wasting cachexia in pancreatic cancer. By inhibiting ZIP4, they hope to prevent cachexia and improve treatment outcomes for patients with pancreatic cancer.
A new pilot study demonstrated the feasibility of using molecular tumor markers to guide chemotherapy selection in patients with metastatic pancreatic cancer. The study reported promising progression-free survival and overall survival rates, with partial responses seen in 28% of patients.
Researchers have identified a biomarker that can accurately predict which pancreatic cysts are likely to become cancerous, offering new hope for improved diagnosis and treatment. The biomarker, mAb Das-1, was found to be more accurate than current methods in predicting cancer risk, with a accuracy rate of 95%.
A recent study by USC researchers found that Native Hawaiians have a 60% increased risk of pancreatic cancer compared to European Americans. The study also revealed that Japanese Americans and African Americans are at a higher risk than previously thought, with increases of 33% and 20%, respectively.
The POLO trial shows that olaparib significantly reduces the risk of disease progression or death in metastatic pancreatic cancer patients with BRCA mutations. Progression-free survival was 7.4 months on the olaparib arm, compared to 3.8 months on the placebo arm.
A study found that pancreatic cancer cells can behave differently based on their surroundings, with some responding better to chemotherapy and radiation. The stroma of tumors consists of connective tissue cells that contribute to tumor growth and spread.
Researchers from Stand Up To Cancer will discuss their work on advancing immunotherapy for pediatric brain tumors, genome-wide cell-free DNA fragmentation profiling for early cancer detection, and personalized consolidation immunotherapy in localized non-small cell lung cancer. The findings highlight promising approaches to screening, ...
Seven cutting-edge research projects have been awarded grants to tackle pancreatic cancer, with a focus on early diagnosis, potential new treatments, and understanding immunotherapy's limitations.
A new study found that one-third of patients with metastatic pancreatic cancer do not see a medical oncologist, and even more do not receive cancer-directed treatment. The data suggest that there are many missed opportunities for important discussions between patients and cancer specialists.
Eight researchers from the University of Texas M. D. Anderson Cancer Center have been awarded $100,000 fellowships to conduct high-impact cancer research over two years. The Andrew Sabin Family Fellowship Program aims to encourage creativity and innovation in cancer research.
Researchers found that removing the ATDC gene from pancreatic cells prevented the development of pancreatic cancer in mice. The study identified ATDC as a key player in the reprogramming of adult cells into primitive, high-growth cell types, which can lead to cancer.